Last reviewed · How we verify

Mebeverine+Simethicone — Competitive Intelligence Brief

Mebeverine+Simethicone (Mebeverine+Simethicone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antispasmodic + antifoaming agent combination. Area: Gastroenterology.

phase 3 Antispasmodic + antifoaming agent combination Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Mebeverine+Simethicone (Mebeverine+Simethicone) — Abbott. Mebeverine relaxes smooth muscle in the gastrointestinal tract while simethicone reduces gas bloating by breaking down gas bubbles.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mebeverine+Simethicone TARGET Mebeverine+Simethicone Abbott phase 3 Antispasmodic + antifoaming agent combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antispasmodic + antifoaming agent combination class)

  1. Abbott · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mebeverine+Simethicone — Competitive Intelligence Brief. https://druglandscape.com/ci/mebeverine-simethicone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: